Scarica l'app Stockscreener
436.00
0.45%
1.97
Dopo l'orario di chiusura:
435.00
-1.00
-0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$434.03
Aprire:
$428.68
Volume 24 ore:
1.43M
Relative Volume:
0.86
Capitalizzazione di mercato:
$111.96B
Reddito:
$11.10B
Utile/perdita netta:
$-988.90M
Rapporto P/E:
-111.22
EPS:
-3.92
Flusso di cassa netto:
$-1.26B
1 W Prestazione:
-0.60%
1M Prestazione:
-11.46%
6M Prestazione:
-3.32%
1 anno Prestazione:
-3.28%
Intervallo 1D:
$427.43
$436.59
Intervallo di 1 settimana:
$427.43
$448.00
Portata 52W:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
2 Monster Growth Stocks to Buy and Hold for 10 Years - The Motley Fool
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline? (NASDAQ:VRTX) - Seeking Alpha
Argus Adjusts Price Target on Vertex Pharmaceuticals to $525 From $550 - marketscreener.com
Vertex Pharmaceuticals (VRTX) Downgraded Due to High Inventory Levels | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces $4 Billion Share Buyback Program - GuruFocus
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
Vertex Pharma announces new share buybacks worth up to $4B - MSN
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - Yahoo Finance
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Benzinga
Vertex Pharma stock gains on share buybacks (VRTX:NASDAQ) - Seeking Alpha
Vertex Pharmaceuticals (VRTX) Announces New $4 Billion Stock Rep - GuruFocus
Vertex Pharmaceuticals Authorizes $4 Billion In Additional Share Repurchases - marketscreener.com
August 15th Options Now Available For Vertex Pharmaceuticals (VRTX) - Nasdaq
VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss - Yahoo Finance
Vertex to Participate in Upcoming Investor Conferences | VRTX Stock News - GuruFocus
Vertex to Participate in Upcoming Investor Conferences - Business Wire
Vertex Pharmaceuticals Holds Annual Shareholder Meeting - TipRanks
Stifel maintains hold on Vertex stock with $494 target - Investing.com
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
Best Biotech Stocks to Buy in 2025 - MarketBeat
Fund Update: TRILLIUM ASSET MANAGEMENT, LLC added 38,854 shares of VERTEX PHARMACEUTICALS ($VRTX) to their portfolio - Nasdaq
Our future journey in cystic fibrosis - Vertex Pharmaceuticals
Vertex says late-stage studies of VX-659 triple combination therapy in CF hit main goals - FirstWord Pharma
ViewPoints: Vertex settles on a dynastic successor - FirstWord Pharma
Vertex's VX-445 triple combination regimen achieves main goals of two late-stage studies in CF - FirstWord Pharma
Vertex moves forward with regulatory filings after selecting VX-445 for triple-combination regimen in CF - FirstWord Pharma
Is Vertex Pharmaceuticals (VRTX) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? - Benzinga
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - MSN
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft - CNBC
Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment - Insider Monkey
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Incorporated Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks - MSN
Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss - MSN
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Vertex Says 20,000 Prescriptions Filled for Non-Opioid Pain Drug - MSN
Leerink Partners Downgrades Vertex Pharmaceuticals (XTRA:VX1) - Nasdaq
Vertex Pharmaceuticals (VRTX) Faces Downgrade After Q1 Revenue Miss - GuruFocus
Vertex Pharma stock downgraded at Wolfe (VRTX:NASDAQ) - Seeking Alpha
Cystic fibrosis Market: Epidemiology, Therapies, Companies, - openPR.com
Leerink Partners Downgrades Vertex Pharmaceuticals (BIT:1VRTX) - Nasdaq
Vertex Pharmaceuticals (VRTX) Sees Target Price Increase to $499 by Barclays | VRTX Stock News - GuruFocus
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - AOL.com
Leerink Partners Downgrades Vertex Pharmaceuticals (WBAG:VRTX) - Nasdaq
Wolfe Research Downgrades Vertex Pharmaceuticals to Peer Perform From Outperform - marketscreener.com
Vertex Pharmaceuticals (VRTX) Downgraded Amid Revenue Concerns | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.39%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):